Harrow Sees Q4 EPS $0.40, Revenues $88.8M; EPS Estimate Plunges 666.7%
Harrow forecasts Q4 Dec 2025 EPS of $0.40, marking a 60% YoY gain alongside projected revenues of $88.8 million, up 32.9%. Analysts have slashed its consensus EPS estimate by 666.7% over the past month, resulting in a negative Earnings ESP of -0.42%.
1. Q4 Fiscal 2025 Guidance
Harrow projects earnings of $0.40 per share for the quarter ending December 2025, representing a 60% increase from the prior year. The company also anticipates revenues of $88.8 million, up 32.9% year over year, reflecting ongoing growth in its core medical-drug portfolio.
2. Analyst Estimate Revisions
Over the last 30 days, Wall Street analysts have collectively reduced Harrow's consensus EPS estimate by 666.7%, driving the forecast down to $0.40. This sharp adjustment has produced an Earnings ESP of -0.42%, signaling a higher probability of reporting below-consensus results.
3. Market Implications
A negative Earnings ESP typically indicates a likely earnings miss, which could pressure Harrow's shares upon release. Investors will be watching the upcoming report closely for any commentary on sales momentum and cost management that might alter near-term expectations.